R. Kirk

发表

High drug attrition rates—where are we going wrong?

L. Hutchinson, R. Kirk, 2011, Nature Reviews Clinical Oncology.

A manually annotated Actinidia chinensis var. chinensis (kiwifruit) genome highlights the challenges associated with draft genomes and gene prediction in plants

Charles David, Robert J. Schaffer, William A. Laing, 2018, BMC Genomics.

Risk factors: Oncotype DX® assay predicts local recurrence in breast cancer

R. Kirk, 2010, Nature Reviews Clinical Oncology.

Breast cancer: Circulating tumour DNA the better of the blood biomarkers

R. Kirk, 2013, Nature Reviews Clinical Oncology.

Gastrointestinal cancer: New drug shows promise in refractory colorectal cancer

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Genetics: Glioblastoma landscape revealed

R. Kirk, 2013, Nature Reviews Clinical Oncology.

Targeted therapies: Hope for pancreatic neuroendocrine tumors

R. Kirk, 2011, Nature Reviews Clinical Oncology.

Targeted therapies: Model reveals addiction to oncogenes

R. Kirk, 2011, Nature Reviews Clinical Oncology.

Breast cancer: Resource poor but ingenuity rich

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Renal fibrosis: KIM-1 expression links kidney injury with CKD in mice

R. Kirk, 2013, Nature Reviews Nephrology.

Immunotherapy: A first for first-line therapy in NSCLC

R. Kirk, 2011, Nature Reviews Clinical Oncology.

Pancreatic cancer: Mouse models link metabolism and deubiquitination with Kras

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Lung cancer: Maintenance chemotherapy—a stitch in time saves nine?

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Haematological cancer: New standard of care?

R. Kirk, 2013, Nature Reviews Clinical Oncology.

Disease prevention: Pain killer—cancer preventer

R. Kirk, 2011, Nature Reviews Clinical Oncology.

Immunotherapy: Adoptive cell therapy simplified

R. Kirk, 2013, Nature Reviews Clinical Oncology.

Targeted therapies: New standard of therapy for HER2-positive gastric cancers?

R. Kirk, 2010, Nature Reviews Clinical Oncology.

Milestone 19: Dynamic protein structures

R. Kirk, 2015 .

From ASCO—immunotherapy: Programming cancer cell death

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Targeted therapies: New targets in Burkitt lymphoma?

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Targeted therapies: A new success for an antiangiogenic?

R. Kirk, 2011, Nature Reviews Clinical Oncology.

Clinical trials in CNS--SMi's eighth annual conference.

R. Kirk, 2010, IDrugs : the investigational drugs journal.

Targeted therapies: The maths behind combination therapy

R. Kirk, 2013, Nature Reviews Clinical Oncology.

Pediatric oncology: Pulsed treatment in continuation therapy improves disease-free survival in children with hematologic malignancies

R. Kirk, 2010, Nature Reviews Clinical Oncology.

Regulation of lignin biosynthesis in fruit pericarp hardening of mangosteen (Garcinia mangostana L.) after impact

A. Allan, I. Ferguson, R. Kirk, 2014 .

A manually annotated Actinidia chinensis var. chinensis (kiwifruit) genome highlights the challenges associated with draft genomes and gene prediction in plants

Dawei Li, R. Hellens, R. Storey, 2018, BMC Genomics.

Oncology trials—the elephant in the room

L. Hutchinson, R. Kirk, 2012, Nature Reviews Clinical Oncology.

Patient profiling in breast cancer—is knowledge power?

L. Hutchinson, R. Kirk, M. Villanueva, 2011, Nature Reviews Clinical Oncology.

Structural adaptation of the plant protease Deg1 to repair photosystem II during light exposure

M. Ehrmann, T. Clausen, R. Kirk, 2011, Nature Structural &Molecular Biology.

Regulation of the sigmaE stress response by DegS: how the PDZ domain keeps the protease inactive in the resting state and allows integration of different OMP-derived stress signals upon folding stress.

R. Kurzbauer, M. Ehrmann, T. Clausen, 2007, Genes & development.

Combination therapy: Can less really be more in melanoma?

R. Kirk, 2011, Nature Reviews Clinical Oncology.

Structural and functional analysis of the proteasome inhibitor PI31 and its interaction with the F-box protein Fbxo 7

R. Kirk, 2005 .

Structure of a Conserved Dimerization Domain within the F-box Protein Fbxo7 and the PI31 Proteasome Inhibitor*

J. Murray-Rust, H. Laman, P. Knowles, 2008, Journal of Biological Chemistry.

Haematological cancer: First randomized study

R. Kirk, 2013, Nature Reviews Clinical Oncology.

Breast cancer: High-dose fulvestrant is a safe and effective therapy for breast cancer

R. Kirk, 2010, Nature Reviews Clinical Oncology.

Tumour evolution: Evidence points to the existence of cancer stem cells

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Clinical trials: High-impact session from kidney week

R. Kirk, 2014, Nature Reviews Nephrology.

Diagnosis: Dying from a cancer diagnosis

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Genetics: A new tool for the KIT

R. Kirk, 2011, Nature Reviews Clinical Oncology.

Gastrointestinal cancer: Combine and conquer

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Palliative care: Steroids to combat fatigue

R. Kirk, 2013, Nature Reviews Clinical Oncology.

Targeted therapies: STAT3 and EGFR target resistance

R. Kirk, 2012, Nature Reviews Clinical Oncology.

Hematology: Long-term response in high-risk CLL

R. Kirk, 2010, Nature Reviews Clinical Oncology.

Genetics: The COGS are turning in breast, ovarian and prostate cancer

R. Kirk, 2013, Nature Reviews Clinical Oncology.

Genetics: Causative genes identified in rare renal ciliopathies

R. Kirk, 2014, Nature Reviews Nephrology.